{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:05:58Z","timestamp":1784261158745,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112821","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:50:22Z","timestamp":1784260222000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and Therapeutic Challenges in Asthma and Chronic Obstructive Pulmonary Disease Overlap: A Four-Patient Case Series"],"prefix":"10.7759","author":[{"given":"Benedict","family":"Amalraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Marrero Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerja","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1055","article-title":"Defining the asthma-COPD overlap syndrome in a COPD cohort","volume":"149","author":"Cosio BG","year":"2016","unstructured":"Cosio BG, Soriano JB, L\u00f3pez-Campos JL, et al.. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016, 149:45-52. 10.1378\/chest.15-1055","journal-title":"Chest"},{"key":"ref2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. (2024). Accessed. July 1, 2026:  https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf."},{"key":"ref3","unstructured":"2026 GOLD Report and Pocket Guide. Global strategy for prevention, diagnosis and management of COPD. 2026 report. (2026). Accessed: July 1, 2026: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S85363","article-title":"Clinical characteristics of the asthma-COPD overlap syndrome--a systematic review","volume":"10","author":"Nielsen M","year":"2015","unstructured":"Nielsen M, B\u00e5rnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome--a systematic review. Int J Chron Obstruct Pulmon Dis. 2015, 10:1443-54. 10.2147\/COPD.S85363","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100848","article-title":"A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: findings from the PRISM study","volume":"16","author":"Shim JS","year":"2023","unstructured":"Shim JS, Kim H, Kwon JW, et al.. A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: findings from the PRISM study. World Allergy Organ J. 2023, 16:100848. 10.1016\/j.waojou.2023.100848","journal-title":"World Allergy Organ J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1198-4","article-title":"Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis","volume":"20","author":"Hosseini M","year":"2019","unstructured":"Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019, 20:229. 10.1186\/s12931-019-1198-4","journal-title":"Respir Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201705-0973WS","article-title":"American Thoracic Society\/National Heart, Lung, and Blood Institute asthma-chronic obstructive pulmonary disease overlap workshop report","volume":"196","author":"Woodruff PG","year":"2017","unstructured":"Woodruff PG, van den Berge M, Boucher RC, et al.. American Thoracic Society\/National Heart, Lung, and Blood Institute asthma-chronic obstructive pulmonary disease overlap workshop report. Am J Respir Crit Care Med. 2017, 196:375-81. 10.1164\/rccm.201705-0973WS","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","unstructured":"Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of diseases of chronic airflow limitation. asthma, COPD and asthma-COPD overlap syndrome. (2015). Accessed: 01\/28\/2024: https:\/\/goldcopd.org\/wp-content\/uploads\/2016\/04\/GOLD_ACOS_2015.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00436-2016","article-title":"What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion","volume":"48","author":"Sin DD","year":"2016","unstructured":"Sin DD, Miravitlles M, Mannino DM, et al.. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016, 48:664-73. 10.1183\/13993003.00436-2016","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe S","year":"2019","unstructured":"Pascoe S, Barnes N, Brusselle G, et al.. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019, 7:745-56. 10.1016\/S2213-2600(19)30190-0","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel M","year":"2018","unstructured":"Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fager\u00e5s M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018, 6:117-26. 10.1016\/S2213-2600(18)30006-7","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.15","article-title":"The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol","volume":"129","author":"Nelson HS","year":"2006","unstructured":"Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006, 129:15-26. 10.1378\/chest.129.1.15","journal-title":"Chest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011721.pub2","article-title":"Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma","volume":"2016","author":"Kew KM","year":"2016","unstructured":"Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA\/ICS) versus LABA\/ICS for adults with asthma. Cochrane Database Syst Rev. 2016, 2016:CD011721. 10.1002\/14651858.CD011721.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30055-3","article-title":"Biologicals for asthma in patients with asthma-COPD overlap","volume":"5","author":"Busse WW","year":"2017","unstructured":"Busse WW. Biologicals for asthma in patients with asthma-COPD overlap.  Lancet Respir Med. 2017, 5:175-7. 10.1016\/S2213-2600(17)30055-3","journal-title":"Lancet Respir Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S338467","article-title":"The response to biologics is better in patients with severe asthma than in patients with asthma-COPD overlap syndrome","volume":"15","author":"P\u00e9rez de Llano L","year":"2022","unstructured":"P\u00e9rez de Llano L, Dacal Rivas D, Marina Malanda N, et al.. The response to biologics is better in patients with severe asthma than in patients with asthma-COPD overlap syndrome. J Asthma Allergy. 2022, 15:363-9. 10.2147\/JAA.S338467","journal-title":"J Asthma Allergy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt SP","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al.. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023, 389:205-14. 10.1056\/NEJMoa2303951","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt SP","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al.. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024, 390:2274-83. 10.1056\/NEJMoa2401304","journal-title":"N Engl J Med"},{"key":"ref18","unstructured":"U.S. Food and Drug Administration. BLA 761055\/S-064 supplement approval letter (dupixent\/dupilumab-COPD eosinophilic phenotype). (2024). Accessed. 02\/19\/2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/761055Orig1s064ltr.pdf."},{"key":"ref19","unstructured":"U.S. Food and Drug Administration. Dupixent (dupilumab) injection, for subcutaneous use. prescribing information. (2024). Accessed: 02\/19\/2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s064lbl.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2026.2689394","article-title":"Number needed to treat with biologics in type-2 inflammation COPD: a systematic review and meta-analysis","volume":"23","author":"Wang Q","year":"2026","unstructured":"Wang Q, Ma Q. Number needed to treat with biologics in type-2 inflammation COPD: a systematic review and meta-analysis. COPD. 2026, 23:2689394. 10.1080\/15412555.2026.2689394","journal-title":"COPD"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224908-diagnostic-and-therapeutic-challenges-in-asthma-and-chronic-obstructive-pulmonary-disease-overlap-a-four-patient-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:50:28Z","timestamp":1784260228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224908-diagnostic-and-therapeutic-challenges-in-asthma-and-chronic-obstructive-pulmonary-disease-overlap-a-four-patient-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.112821","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}